alectinib

• Non-small Cell Lung Cancer (NSCLC)
• Treatment of ALK-positive stage IV NSCLC (designated an orphan drug by FDA for this use).
• Guidelines for the treatment of stage IV NSCLC in patients with driver alterations in ALK generally support use of alectinib as an option in the first-line setting and in the second-line setting following therapy with crizotinib.
• Confirmation of ALK rearrangement necessary prior to initiation of therapy.

Backlink

• non-small cell lung cancers
• NSCLC
• Adeno or Other in Stage IV NSCLC Treatment
• ALK